S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:PAND

Pandion Therapeutics Stock Forecast, Price & News

$59.89
-1.60 (-2.60 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$59.79
Now: $59.89
$61.45
50-Day Range
$17.51
MA: $26.21
$61.63
52-Week Range
$10.28
Now: $59.89
$62.90
Volume346,930 shs
Average Volume397,243 shs
Market Capitalization$1.77 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pandion Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprised of an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases. The company's other product candidates comprise PT627, a systemic PD-1 agonist that is in preclinical studies for the treatment of autoimmune diseases; PT001, a bifunctional molecule combining its PD-1 agonist effector with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM) to drive tissue-selective immunomodulation in the gastrointestinal tract; and PT002, a bifunctional molecule combining its IL-2 mutein effector with a tether module that binds to MAdCAM to drive tissue-selective immunomodulation in the gastrointestinal tract. It has a collaboration with Astellas Pharma Inc. to develop locally acting immunomodulators for autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.
Pandion Therapeutics logo

Headlines

Why Pandion Therapeutics Stock Blasted Sky-High on Thursday
February 25, 2021 |  finance.yahoo.com
Merck to Buy Autoimmune Drug Developer for $1.85 Billion
February 25, 2021 |  finance.yahoo.com
Is PAND A Good Stock To Buy Now?
December 13, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PAND
CUSIPN/A
CIKN/A
Phone617-393-5925
Employees43
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$970,000.00

Profitability

Miscellaneous

Market Cap$1.77 billion
Next Earnings Date3/8/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.98 out of 5 stars

Medical Sector

1055th out of 1,972 stocks

Pharmaceutical Preparations Industry

480th out of 772 stocks

Analyst Opinion: 1.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$59.89
-1.60 (-2.60 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PAND News and Ratings via Email

Sign-up to receive the latest news and ratings for PAND and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pandion Therapeutics (NASDAQ:PAND) Frequently Asked Questions

Is Pandion Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pandion Therapeutics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Pandion Therapeutics stock.
View analyst ratings for Pandion Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Pandion Therapeutics?

Wall Street analysts have given Pandion Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pandion Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Pandion Therapeutics?

Pandion Therapeutics saw a increase in short interest in the month of February. As of February 12th, there was short interest totaling 483,700 shares, an increase of 50.1% from the January 28th total of 322,200 shares. Based on an average trading volume of 116,700 shares, the days-to-cover ratio is currently 4.1 days. Approximately 4.1% of the shares of the company are short sold.
View Pandion Therapeutics' Short Interest
.

When is Pandion Therapeutics' next earnings date?

Pandion Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Pandion Therapeutics
.

How were Pandion Therapeutics' earnings last quarter?

Pandion Therapeutics, Inc. (NASDAQ:PAND) announced its quarterly earnings data on Monday, November, 16th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.07. The firm earned $2.63 million during the quarter, compared to the consensus estimate of $1 million.
View Pandion Therapeutics' earnings history
.

What price target have analysts set for PAND?

4 brokerages have issued twelve-month target prices for Pandion Therapeutics' shares. Their forecasts range from $28.00 to $60.00. On average, they anticipate Pandion Therapeutics' share price to reach $44.25 in the next year. This suggests that the stock has a possible downside of 26.1%.
View analysts' price targets for Pandion Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Pandion Therapeutics' key executives?

Pandion Therapeutics' management team includes the following people:
  • Dr. Rahul Kakkar, CEO & Director (Age 46, Pay $483.67k)
  • Dr. Joanne L. Viney Ph.D., Pres & Chief Scientific Officer (Age 55, Pay $543.01k)
  • Mr. Vikas Goyal, Sr. VP of Bus. Devel. (Age 42, Pay $146.25k)
  • Mr. Edward D. Freedman J.D., Esq., Chief Operating Officer (Age 52)
  • Dr. John S. Sundy M.D., Ph.D., Chief Medical Officer (Age 59)
  • Mr. Nathan Higginson-Scott Ph.D., VP of Research & Head of Biotherapeutics
  • Mr. Kevin Otipoby Ph.D., VP of Research & Head of Immunology
  • Ms. Kata Kis-Toth Ph.D., Director & Head of Translational Sciences

Who are some of Pandion Therapeutics' key competitors?

What other stocks do shareholders of Pandion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pandion Therapeutics investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Moderna (MRNA), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Curaleaf (CURLF), Dynavax Technologies (DVAX), Evofem Biosciences (EVFM), (NGM) and OPKO Health (OPK).

When did Pandion Therapeutics IPO?

(PAND) raised $94 million in an initial public offering on Friday, July 17th 2020. The company issued 5,500,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley, SVB Leerink and BMO Capital Markets served as the underwriters for the IPO.

What is Pandion Therapeutics' stock symbol?

Pandion Therapeutics trades on the NASDAQ under the ticker symbol "PAND."

When did Pandion Therapeutics' lock-up period expire?

Pandion Therapeutics' lock-up period expired on Wednesday, January 13th. Pandion Therapeutics had issued 7,500,000 shares in its IPO on July 17th. The total size of the offering was $135,000,000 based on an initial share price of $18.00. Since the end of Pandion Therapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who are Pandion Therapeutics' major shareholders?

Pandion Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (2.71%), BlackRock Inc. (2.38%), Alyeska Investment Group L.P. (0.30%), Alyeska Investment Group L.P. (0.30%), JPMorgan Chase & Co. (0.12%) and Nuveen Asset Management LLC (0.10%). Company insiders that own Pandion Therapeutics stock include Daniel J Becker and Plc Glaxosmithkline.
View institutional ownership trends for Pandion Therapeutics
.

Which major investors are selling Pandion Therapeutics stock?

PAND stock was sold by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board.
View insider buying and selling activity for Pandion Therapeutics
or view top insider-selling stocks.

Which major investors are buying Pandion Therapeutics stock?

PAND stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Federated Hermes Inc., JPMorgan Chase & Co., Nuveen Asset Management LLC, Alyeska Investment Group L.P., Alyeska Investment Group L.P., State of Wisconsin Investment Board, and Wells Fargo & Company MN. Company insiders that have bought Pandion Therapeutics stock in the last two years include Daniel J Becker, and Plc Glaxosmithkline.
View insider buying and selling activity for Pandion Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Pandion Therapeutics?

Shares of PAND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pandion Therapeutics' stock price today?

One share of PAND stock can currently be purchased for approximately $59.89.

How much money does Pandion Therapeutics make?

Pandion Therapeutics has a market capitalization of $1.77 billion and generates $970,000.00 in revenue each year.

How many employees does Pandion Therapeutics have?

Pandion Therapeutics employs 43 workers across the globe.

What is Pandion Therapeutics' official website?

The official website for Pandion Therapeutics is www.pandiontx.com.

Where are Pandion Therapeutics' headquarters?

Pandion Therapeutics is headquartered at 134 COOLIDGE AVENUE 2ND FLOOR, WATERTOWN MA, 02472.

How can I contact Pandion Therapeutics?

Pandion Therapeutics' mailing address is 134 COOLIDGE AVENUE 2ND FLOOR, WATERTOWN MA, 02472. The company can be reached via phone at 617-393-5925 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.